v3.23.2
Note 4 - Asset Acquisition - Consideration for Acquisition (Details) - Lowell Therapeutics [Member]
$ in Thousands
Jan. 07, 2022
USD ($)
Payments to Acquire Businesses, Gross $ 3,536
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 6,000
Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations, Value 800 [1]
Business Acquisition, Transaction Costs 2,521
Business Combination, Consideration Transferred, Total 12,368
Cash acquired (3,549)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total 8,819 [2]
Common Stock [Member]  
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 5,161
Common Stock to Settle Transaction Costs [Member]  
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable $ 350
[1] Recorded as Other long-term liabilities in the Condensed Consolidated Balance Sheets.
[2] Recorded as In-process research and development asset in the Condensed Consolidated Balance Sheets.